Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MicroPort NeuroTech Limited ( (HK:2172) ) has issued an update.
MicroPort NeuroTech Limited announced its unaudited interim results for the first half of 2025, reporting a revenue of approximately RMB382.9 million. The company experienced a significant 67.4% increase in overseas business revenue compared to the previous year, driven by strong sales across various regions. However, the revenue from flow-diverting stents decreased due to volume-based procurements, and cerebral atherosclerotic stenosis products were impacted by the termination of previous distribution agreements. Despite these challenges, the company achieved a net profit of RMB92.7 million and declared an interim dividend of HK$0.05 per share.
The most recent analyst rating on (HK:2172) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.
More about MicroPort NeuroTech Limited
MicroPort NeuroTech Limited operates in the medical technology industry, focusing primarily on products for hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company is known for its innovative solutions in the neurovascular field, with a market focus that spans across Asia Pacific, North America, Latin America, and Europe, the Middle East, and Africa.
Average Trading Volume: 17,060,544
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.51B
For an in-depth examination of 2172 stock, go to TipRanks’ Overview page.